GlaxoSmithKline and Pfizer are in line for exits after oncology drug developer SpringWorks filed to float on the Nasdaq Global Market.

Shin Nippon spinoff Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.

CAS-backed X-ray technology developer XpectVision Technology has added $14.2m to its coffers to drive the development of its mammography device.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Gene therapy developer Renovacor, a Temple University spinout, has secured series A funding from investors including Novartis Venture Fund.

Novartis Venture Fund co-led the gene therapy developer's series A round, raised as it prepares to submit an investigational new drug application for its lead drug.

SnapGene, a molecular biology documentation spinout of UChicago, has been acquired by scientific data analysis tool provider GraphPad Software.

Osage University Partners is among the series B investors backing Virginia Tech-linked IBD therapy disease developer Landos Biopharma, which is preparing phase 2 trials.

Novartis and Eli Lilly are exiting the neurological disease therapy developer in an acquisition that will involve $52.5m upfront and up to $250m in milestone payments.